Disclaimer: This is not legal advice or financial advice and I do not own any Treace stock. OK, not let's dive in.
The orthopedic startup world isn’t for the faint of heart. When you disrupt an entrenched market like bunion correction, you invite copycats, competitors, and—eventually—lawsuits.
Today's press release about the class action lawsuit - Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medical Concepts, Inc. (TMCI) And Encourages Investors to Connect
Treace Medical (TMCI) is now squarely in that storm. A shareholder class action is brewing, alleging that Treace misled investors by downplaying the competitive threat to its flagship Lapiplasty 3D bunion system. On May 7, 2024, when Treace cut its revenue guidance (from ~$220M to ~$201M) and finally admitted that competition—especially minimally invasive osteotomy systems and Lapiplasty “knockoffs”—was biting into demand, the stock cratered 63% in a single day.
The plaintiff’s theory is simple: “Treace knew MIS was stealing cases earlier, but didn’t tell us until it was too late.”
The Case Against Treace
Event-driven drop: Courts love a clean “stock-drop” story. Plaintiffs point to May 7 as the day the ...
